28.26
0.50 (1.80%)
| Previous Close | 27.76 |
| Open | 27.60 |
| Volume | 5,569,401 |
| Avg. Volume (3M) | 7,165,053 |
| Market Cap | 20,225,714,176 |
| Price / Sales | 1.46 |
| Price / Book | 4.71 |
| 52 Weeks Range | |
| Earnings Date | 6 Feb 2026 |
| Operating Margin (TTM) | -4,823.84% |
| Diluted EPS (TTM) | -0.750 |
| Quarterly Revenue Growth (YOY) | -16.10% |
| Quarterly Earnings Growth (YOY) | -96.70% |
| Total Debt/Equity (MRQ) | 1.93% |
| Current Ratio (MRQ) | 33.47 |
| Operating Cash Flow (TTM) | -839.45 M |
| Levered Free Cash Flow (TTM) | -375.20 M |
| Return on Assets (TTM) | -10.73% |
| Return on Equity (TTM) | -12.54% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Roivant Sciences Ltd. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -5.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.30 |
|
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 30.31% |
| % Held by Institutions | 83.49% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Qvt Financial Lp | 31 Dec 2025 | 26,387,021 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 35.00 (Citigroup, 23.85%) | Buy |
| Median | 33.00 (16.77%) | |
| Low | 30.00 (Guggenheim, 6.16%) | Buy |
| Average | 32.80 (16.07%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 25.38 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 04 Mar 2026 | 34.00 (20.31%) | Buy | 28.10 |
| 10 Feb 2026 | 33.00 (16.77%) | Buy | 27.35 | |
| Citigroup | 10 Feb 2026 | 35.00 (23.85%) | Buy | 27.35 |
| Guggenheim | 09 Feb 2026 | 30.00 (6.16%) | Buy | 27.67 |
| Goldman Sachs | 15 Dec 2025 | 33.00 (16.77%) | Buy | 21.90 |
| Leerink Partners | 15 Dec 2025 | 32.00 (13.23%) | Buy | 21.90 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| PULIK RICHARD | - | 27.15 | -1,000 | -27,150 |
| TORTI FRANK | - | 27.48 | -3,000,000 | -82,326,308 |
| VENKER ERIC | - | 27.15 | -7,051 | -191,435 |
| Aggregate Net Quantity | -3,008,051 | |||
| Aggregate Net Value ($) | -82,544,893 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 27.35 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| TORTI FRANK | Officer | 23 Feb 2026 | Sell (-) | 587,390 | 27.76 | 16,305,946 |
| TORTI FRANK | Officer | 23 Feb 2026 | Option execute | 587,390 | - | - |
| TORTI FRANK | Officer | 20 Feb 2026 | Sell (-) | 1,012,610 | 27.15 | 27,492,362 |
| TORTI FRANK | Officer | 20 Feb 2026 | Option execute | 1,012,610 | - | - |
| VENKER ERIC | Officer | 20 Feb 2026 | Disposed (-) | 7,051 | 27.15 | 191,435 |
| PULIK RICHARD | Officer | 20 Feb 2026 | Disposed (-) | 1,000 | 27.15 | 27,150 |
| TORTI FRANK | Officer | 19 Feb 2026 | Sell (-) | 1,400,000 | 27.52 | 38,528,000 |
| TORTI FRANK | Officer | 19 Feb 2026 | Option execute | 1,400,000 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |